Install
The analyzed dataset included over 200,000 patients with vitiligo to find trends in diagnosis, treatment, and more. The findings of the MVOR-1 and MVOR-2 studies are published in JAMA Dermatology, supporting the rosacea drug’s recent FDA approval. Serota and other field experts discussed best practices as well as new t
- 401articles · 365d
- 3+ hour agolatest article
- Dec 9, 2025earliest in window
- 98%with images
- 277avg words
- Medical 398
- Health 378
- Health & Wellness 341
- Beauty & Fitness 55
- Science & Technology 10
- Education 6
- Economy, Business & Finance 3
- Business & Industrial 2
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
CIndU Treatment Algorithm: Antihistamine Up-Titration and Unmet Needs
3+ hour, 13+ min ago (227+ words) A methodical up-titration schedule and clear expectations help patients reach the point where advanced therapy is appropriate. With no approved CIndU medication, clinicians are extrapolating from CSU. In "CIndU Treatment Algorithm: Antihistamine Up-Titration and Unmet Needs," the panel walks through…...
CIndU Antihistamines: Why Second-Generation H1 Therapy Falls Short for Many
3+ hour, 15+ min ago (215+ words) Dermatology Times "CIndU Antihistamines: Why Second-Generation H1 Therapy Falls Short for Many" takes up the question of what standard antihistamine therapy can and cannot deliver Dasilva asks for Dr Finklea's experience and opinions on first- and second-generation antihistamines in CIndU Finklea…...
EB06 Phase 2 Vitiligo Study Receives FDA IND Clearance
3+ hour, 16+ min ago (538+ words) The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027. The FDA recently cleared the investigational new drug (IND) application for a phase 2 study…...
Don't Be Rash: Balancing Topical Steroids in the Era of Nonsteroidals
17+ hour, 24+ min ago (450+ words) On this episode of Don’t Be Rash, host Andrew C. Krakowski, MD, welcomes Lawrence Eichenfield, MD, pediatric dermatologist, to discuss topical corticosteroid potency, dosing, and where they fit alongside nonsteroidal agents. Disclosure: Don’t Be Rash is the official podcast of…...
Reviewing Dermatologic Manifestations of HIV Infection and Acquired Immunodeficiency Syndrome
22+ hour, 4+ min ago (274+ words) This World Aids Day, review the common dermatologic manifestations of AIDS and HIV infection. In a review published in the International Journal of Microbiology, authors Mohseni Afshar et al sought to explore the relationship between HIV and AIDS infection with…...
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
22+ hour, 5+ min ago (386+ words) The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial. The US Food and Drug Administration (FDA) has approved pritelivir (HOVILPRI; Asahi Kasei Therapeutics) 100-mg tablets for…...
How to Choose Oral Antibiotics and Retinoids for Acne Management
1+ day, 4+ hour ago (309+ words) At Fall Clinical 2026, Christopher Bunick, MD, PhD, discussed topical and oral acne management, including tetracycline selection and micronized isotretinoin. “One area my research laboratory has been very involved in is acne research, understanding oral antibiotics and other molecules that we…...
Exosome Progress and Remibrutinib Label Expansion
1+ day, 4+ hour ago (408+ words) At Fall Clinical 2026, Todd Schlesinger, MD, explained recent exosome regulatory progress, the remibrutinib label update for symptomatic dermographism, and ongoing clinical trials at his trial center. Todd Schlesinger, MD, dermatologist, clinical assistant professor at George Washington University School of Medicine…...
Yale - Dept of Dermatology | Strategic Alliance Partnership | Dermatology Times
1+ day, 4+ hour ago (318+ words) Christopher Bunick, MD, PhD, reviews data on investigational atopic dermatitis agents presented at EADV 2026 and biomarker findings for upadacitinib. At Fall Clinical 2026, Christopher Bunick, MD, PhD, discussed topical and oral acne management, including tetracycline selection and micronized isotretinoin. Christopher Bunick,…...
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
1+ day, 4+ hour ago (359+ words) Christopher Bunick, MD, PhD, reviews data on investigational atopic dermatitis agents presented at EADV 2026 and biomarker findings for upadacitinib. Bunick attended EADV at the end of September and described the gathering as a meeting of dermatologists from across the world....